Pfizer will give clinical trial info to patients

Pfizer ($PFE) says it will support the trend toward making more data from clinical trials available by providing easy-to-understand summaries to patients who participate in the independent studies. It says it hopes the move will encourage patients to get into trials, as well as help spur research, Reuters reports. "We are proud to be, I think, the first company to take this step," Pfizer research chief Mikael Dolsten said at a briefing. There is growing public support for making information available, something drugmakers have been loathe to do in the past. European health regulators plan next year to begin publishing the clinical trial data that drugmakers submit with their new drug approvals. Story | More

Suggested Articles

AZ's tremelimumab has so far suffered a host of clinical failures. But new trial results show the company might be able to use the drug in a new way.

Roche may have just grabbed the first FDA nod for a checkpoint med in previously untreated liver cancer, but Merck is hoping it won’t be far behind.

Pfizer’s Ibrance has met with success in breast cancer since breaking onto the scene in 2015. But its first foray into early breast cancer was a bust.